Related Experiment Video
Updated: Jan 12, 2026
04:41
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
8.6K
Non-coding RNA biomarkers in cardiovascular disease.
Asal Golchin1, Naeemeh Hassanpour Ardekanizadeh1, Elaheh Jafari1
1Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|November 2, 2025
Summary
Non-coding RNAs (ncRNAs) show promise as novel biomarkers for cardiovascular diseases (CVDs), offering improved detection and prognosis. Further research is needed to overcome challenges for clinical application.
Area of Science:
- Biomedical research
- Molecular diagnostics
- Cardiovascular medicine
Background:
- Cardiovascular disease (CVD) is a leading global health issue, with rising prevalence in low- and middle-income countries.
- Hypertension is a critical modifiable risk factor for CVD.
- Current diagnostic methods for CVD, like troponins and natriuretic peptides, have limitations in sensitivity, specificity, and accessibility.
Purpose of the Study:
- To review the significance of non-coding RNAs (ncRNAs) as diagnostic biomarkers for CVDs.
- To compare ncRNAs with existing diagnostic markers for CVD.
- To highlight clinical studies and applications of ncRNAs in CVD diagnosis and prognosis.
Main Methods:
- Literature review focusing on non-coding RNAs in cardiovascular disease.
- Analysis of clinical studies investigating ncRNA biomarkers.
- Comparison of ncRNA diagnostic potential against established CVD markers.
Main Results:
- Non-coding RNAs (ncRNAs) demonstrate stability, disease-specific expression, and minimally invasive detection.
- ncRNAs present a promising alternative to current CVD diagnostic tools.
- Clinical studies show potential for ncRNAs in CVD diagnosis, prognosis, and treatment.
Conclusions:
- Non-coding RNAs (ncRNAs) are emerging as valuable biomarkers for cardiovascular diseases (CVDs).
- Challenges in standardization and reproducibility require further investigation for clinical translation.
- Additional research is essential to fully realize the potential of ncRNAs in CVD management.
More Related Videos
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
529
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
529
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
777
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
777
01:30Coronary Artery Disease I: Introduction
868
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
868
02:39lncRNA - Long Non-coding RNAs
3.5K
3.5K
02:39lncRNA - Long Non-coding RNAs
9.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
379
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
379